Table 1 | Effect of potassium-adaptation on the lipid..

Treatment	Total cholesterol	HDL	LDL	Triglyceride
C (2ml/kg)	61.81± 3.52	28.59± 3.42	22.86± 2.47	75.20± 10.93
A	65.78± 2.27 ^ad	51.55± 0.27 ^{a, ad}	6.89± 1.25 ^{a, ad}	46.07± 1.31^ad
G	66.51± 6.44 ^ad	20.41± 2.78	45.84± 5.92 ^b	42.81± 5.75^b
AG	45.88± 5.50	27.19± 3.00	33.95± 10.11	35.75± 2.90
K	44.32± 5.95 ^b	47.68± 1.75 ^b	12.07± 2.80 ^b	26.82± 6.94^b
KAG	49.71± 4.92	35.76± 2.51 ^ac	8.91± 0.46	33.43± 5.89
D	60.13± 6.35	20.12± 2.89	33.10± 3.42 ^b	46.55± 7.87^b
DG	71.84± 2.83	75.38± 8.46 ^ab	7.97± 2.27 ^ab	34.20± 8.11^ab
DGA	50.74± 4.95	33.34± 2.15	12.45± 3.19	52.81± 4.03
KDAG	30.93± 6.12 ^ab	14.59± 1.56 ^ab	15.82± 4.48	57.44± 6.58

Values are mean + SEM.
(n=5 per group).
^ap<0.0001, ^bp<0.05 significantly different from the control, ^abp<0.05 significantly different from the diabetic group treated with glibenclamide and amlodipine, ^acp<0.05
significantly different from the potassium adapted group and ^cp<0.05 significantly different from the normal group treated with amlodipine and glibenclamide.
C: Control (normal saline group)
A: Normal group treated with amlodipine
G : Normal group treated with glibenclamide
AG: Normal group treated with both amlodipine and glibenclamide
K: Potassium adapted group
KAG: Potassium adapted treated with both glibenclamide and amlodipine
D: Diabetic group
DG: Diabetic group treated with glibenclamide
DGA: Non-adapted diabetic group treated with both glibenclamide and amlodipine
KDAG: potassium adapted diabetic group treated with both amlodipine and glibenclamide

Table 1: Effect of potassium-adaptation on the lipid profile of normal and streptozotocin-induced diabetic rats treated with amlodipine (5 mg/kg) and glibenclamide (5 mg/ kg).

Goto home»